RT Journal Article
T1 Response of RAW 264.7 and J774A.1 macrophages to particles and nanoparticles of a mesoporous bioactive glass: A comparative study
A1 Feito Castellano, María José
A1 Casarrubios Molina, Laura
A1 Oñaderra Sánchez, Mercedes
A1 Gómez Duro, M.
A1 Arribas, P.
A1 Polo Montalvo, A.
A1 Arcos Navarrete, Daniel
A1 Portolés Pérez, María Teresa
A1 Vallet Regí, María Dulce Nombre
AB Mesoporous bioactive glasses (MBGs) are bioceramics designed to induce bone tissue regeneration and very useful materials with the ability to act as drug delivery systems. MBGs can be implanted in contact with bone tissue in different ways, as particulate material, in 3D scaffolds or as nanospheres. In this work, we assessed the effects of particles of mesoporous bioactive glass MBG-75S and mesoporous nanospheres NanoMBG-75S on RAW 264.7 and J774A.1 macrophages, which present different sensitivity and are considered as ideal models for the study of innate immune response. After evaluating several cellular parameters (morphology, size, complexity, proliferation, cell cycle and intracellular content of reactive oxygen species), the action MBG-75S particles and NanoMBG-75S on the polarization of these macrophages towards the pro-inflammatory (M1) or reparative (M2) phenotype was determined by the expression of specific M1 (CD80) and M2 (CD206, CD163) markers. We previously measured the adsorption of albumin and fibrinogen on MBG-75S particles and the production of pro-inflammatory cytokines as TNF-α and IL-6 by macrophages in response to these particles. This comparative study demonstrates that particles of mesoporous bioactive glass MBG-75S and mesoporous nanospheres NanoMBG-75S allow the appropriated development and function of RAW 264.7 and J774A.1 macrophages and do not induce polarization towards the M1 pro-inflammatory phenotype. Therefore, considering that these mesoporous biomaterials offer the possibility of loading drugs into their pores, the results obtained indicate their high potential for use as drug-delivery systems in bone repair and osteoporosis treatments without triggering an adverse inflammatory response.
PB Elsevier
SN 0927-7765
YR 2021
FD 2021-09-07
LK https://hdl.handle.net/20.500.14352/4444
UL https://hdl.handle.net/20.500.14352/4444
LA eng
NO RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)RESEARCHER ID L-6167-2014 (Daniel Arcos Navarrete)ORCID 0000-0002-5367-7272 (Daniel Arcos Navarrete)RESEARCHER ID U-1678-2017 (María Teresa Portolés Pérez)ORCID 0000-0002-9681-0184 (María Teresa Portolés Pérez)
NO Unión Europea. H2020
NO Ministerio de Ciencia e Innovación (MICINN)
DS Docta Complutense
RD 3 may 2024